Pre-Submission Review for Oncology Journals: What Cancer Cell and JCO Reviewers Expect
Oncology manuscripts face unique scrutiny on clinical endpoints, translational depth, patient outcomes, and reporting standards. Here is what reviewers at top oncology journals actually look for.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | Building a point-by-point response that is easy for reviewers and editors to trust. |
Start with | State the reviewer concern clearly, then pair each response with the exact evidence or revision. |
Common mistake | Sounding defensive or abstract instead of specific about what changed. |
Best next step | Turn the response into a visible checklist or matrix before you finalize the letter. |
Decision cue: Oncology is one of the most competitive publishing fields. Cancer Cell desk rejects over 70% of submissions. The Journal of Clinical Oncology (JCO) is similarly selective. The APCs at top oncology journals often exceed $4,000 for open access. The cost of a preventable rejection cycle is not just months of delay. It is potentially thousands of dollars in APC exposure and, for clinical oncology, delayed reporting of evidence that affects patient care.
Check your oncology manuscript readiness in 60 seconds with the free scan.
What makes oncology manuscripts uniquely challenging
The translational expectation
Top oncology journals (Cancer Cell, Nature Cancer, JCO, Lancet Oncology) expect manuscripts to bridge basic science and clinical relevance. A mechanistic study that reveals a new pathway in a cancer cell line needs to show why it matters for patients. A clinical trial needs to show why the results should change practice, not just confirm that a drug has activity.
This dual expectation means oncology manuscripts are evaluated on both scientific rigor AND clinical significance simultaneously. Failing either dimension triggers rejection.
Reporting standards are strict and specific
Oncology has some of the most detailed reporting requirements in biomedical research:
- Clinical trials: CONSORT 2025 (with the recent update), plus oncology-specific extensions
- Biomarker studies: REMARK guidelines
- Prognostic/diagnostic studies: STARD
- Systematic reviews: PRISMA, with oncology-specific considerations for heterogeneous treatment effects
- Preclinical studies: ARRIVE 2.0, plus increasing requirements for patient-derived models
Missing the appropriate reporting guideline at an oncology journal is a fast desk rejection because editors in this field are particularly attuned to reporting quality.
Patient-reported outcomes matter
JCO, Lancet Oncology, and JAMA Oncology increasingly expect patient-reported outcomes (PROs), quality of life data, and patient experience measures alongside traditional clinical endpoints. A trial that shows a progression-free survival benefit without addressing toxicity, quality of life, or patient-reported symptom burden is incomplete by current standards.
The oncology pre-submission checklist
For clinical oncology studies
- clinical trial registered before enrollment (ClinicalTrials.gov, WHO ICTRP)
- CONSORT 2025 checklist complete with page references
- primary endpoint matches registration
- patient-reported outcomes included or justified as absent
- toxicity reporting complete (CTCAE grading)
- overall survival data included or follow-up plan described
- subgroup analyses pre-specified or identified as exploratory
- biomarker correlatives planned and reported per REMARK if applicable
For translational oncology studies
- clinical relevance explicitly stated (not speculative)
- patient-derived models used where appropriate (PDX, organoids)
- validation in independent patient cohorts where feasible
- pathway findings connected to existing therapeutic approaches
- drug resistance mechanisms considered if reporting on targeted therapy
For basic cancer biology
- relevance to human cancer clearly demonstrated (not just mouse models)
- multiple cancer cell lines used (not just one)
- in vivo validation of in vitro findings
- appropriate controls for all genetic perturbation experiments
- data reproducibility across independent experiments documented
For all oncology manuscripts
- appropriate reporting guideline complete
- data deposited (sequencing data in GEO/SRA, clinical trial data per journal policy)
- conflict of interest disclosures complete (especially pharmaceutical relationships)
- statistical methods reviewed independently where possible
Where pre-submission review helps most in oncology
Oncology manuscripts face scrutiny on multiple fronts simultaneously: clinical relevance, scientific rigor, reporting completeness, and ethical compliance. The Manusights free readiness scan evaluates methodology, citation integrity, and journal fit in about 60 seconds.
The $29 AI Diagnostic is particularly valuable for oncology manuscripts because:
- citation verification catches missing references to recent clinical trials that changed the treatment landscape (the field moves fast and missing a landmark trial signals an incomplete literature review)
- figure-level feedback identifies panels with inconsistent data presentation across multiple cell lines or patient cohorts
- journal-specific calibration evaluates readiness against Cancer Cell, JCO, Lancet Oncology, or whichever journal you target
For career-critical oncology submissions, Manusights Expert Review ($1,000 to $1,800) connects you with oncology reviewers who have published in and reviewed for your target journal.
How top oncology journals compare
Feature | Cancer Cell | JCO | Lancet Oncology | JAMA Oncology | Nature Cancer |
|---|---|---|---|---|---|
Scope | Mechanistic cancer biology | Clinical oncology practice | Clinical + global oncology | Clinical practice (JAMA network) | Broad cancer research |
Desk rejection | ~70%+ | ~60% | ~70% | ~65% | ~70% |
Key requirement | Mechanistic + translational | Practice-changing evidence | Global clinical impact | US + international practice | Conceptual advance |
PROs expected | Sometimes | Increasingly yes | Yes | Yes | Sometimes |
Best for | Mechanism-to-treatment bridge | Definitive clinical trials | Global oncology trials | Clinical practice studies | Broad cancer science |
On this page
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Final step
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan. See score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Need deeper scientific feedback? See Expert Review Options
Where to go next
Start here
Same journal, next question
Supporting reads
Conversion step
Find out if this manuscript is ready to submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.